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Introduction
The worldwide prevalence of obesity has doubled since 1980 with more than 13% of adults being obese in 2014 (World Health Organization Fact Sheets, 2016) . Current concerns about the increasing prevalence of obesity derives from obesity being a preventable risk factor for cardiovascular disease, diabetes, musculoskeletal disorders such as arthritis, and some cancers (World Health Organization Fact Sheets, 2016) . In addition, obesity is definitely associated with reproductive disorders and infertility (Pasquali, 2006) .
The comorbidities of obesity are related to body fat distribution, especially to the development of abdominal visceral adiposity (Kershaw and Flier, 2004; Ferrannini et al., 2008) . Visceral adipose tissue is a very active endocrine organ that secretes a large number of inflammatory and immune mediators as well as several hormones collectively known as adipokines (Kershaw and Flier, 2004) . The increased metabolic and cardiovascular risk associated with obesity is mediated by dysfunctional secretion of adipokines, inflammatory mediators and other molecules by excessive visceral adipose tissue (Kershaw and Flier, 2004) .
Activation of the hypothalamic-pituitary-adrenal and renin--angiotensin axes, endothelial dysfunction, increased coagulability and decreased fibrinolysis, low-grade chronic inflammation, increased sympathic tone and local generation of cortisol in adipose tissue all contribute to insulin resistance, glucose intolerance, dyslipidemia, hypertension and/or atherosclerosis in obesity (Fernandez-Real and Ricart, 2003) . Hence, obese persons may present with almost all classic and non-classic cardiovascular risk factors, including surrogate markers derived from molecules involved in these pathophysiological mechanisms, especially if adipose tissue accumulates in the visceral and abdominal depots (Bjorntorp, 1992; Despres and Lemieux, 2006) . Additionally, adipose tissue plays a primary role in the metabolism of hormones secreted by other glands, including sex hormones in both men and women (Kirschner and Samojlik, 1991) .
In humans, the balance of androgens and estrogens result in a clear sexual dimorphism in the distribution of adipose tissue that becomes apparent during puberty (Wells, 2007) . Compared with adult men, women of reproductive age have substantially greater adipose tissue and less lean mass (Wells, 2007) . Premenopausal women are characterized by the deposition of fat in the subcutaneous and glutealfemoral areas whereas men typically show an abdominal and visceral deposition of adipose tissue (Wells, 2007) . Importantly, the association of adipose tissue accumulation and metabolic disorders is stronger for visceral, than for subcutaneous, adipose tissue excess (Ibrahim, 2010) . With advancing age, the differences in accumulation of visceral fat among men and women become less marked as men begin to lose muscle mass from the fifth decade, whereas postmenopausal women, while suffering a similar decline in lean mass, often gain more fat mass than men and increase their amount of visceral fat (Wells, 2007) .
The impact of obesity on gonadal function shows a striking sexual dimorphism ; in women, obesity is associated with androgen excess disorders such as the polycystic ovary syndrome (PCOS) and idiopathic hyperandrogenism (EscobarMorreale et al., 2005) whereas, in men, increasing adiposity may be related to androgen deficiency such as male obesity-associated secondary hypogonadism (MOSH; Saboor Aftab et al., 2013) . We have previously shown that PCOS in women (Escobar-Morreale et al.,
2005) and MOSH in men (Calderon et al., 2016) are among the most frequent comorbidities in severely obese patients submitted to bariatric surgery. Notably, both PCOS and MOSH may resolve after the sustained and marked weight loss usually attained after such a surgical approach, and this occurs in parallel to the amelioration of insulin resistance and the resolution of other metabolic disorders, such as diabetes (Escobar-Morreale et al., 2005; Calderon et al., 2016) , in which adipose tissue dysfunction and excess are the driving forces (Fernandez-Real and Ricart, 2003; Kershaw and Flier, 2004 ). In contrast, resolution of PCOS or secondary hypogonadism seldom occurs when obesity is not involved in their development (Ehrmann, 2005; Rastrelli et al., 2015) .
In 2014, we introduced the term 'obesity-associated gonadal dysfunction' to better describe the subset of patients presenting with PCOS or secondary hypogonadism, in whom obesity and visceral adipose tissue excess and dysfunction appear to play a major causative role, considering the frequent resolution of these gonadal disorders following weight loss .
In obese women, adipose tissue excess and dysfunction may contribute to androgen excess by stimulating the secretion of these hormones by the ovaries and adrenals through the indirect effects of insulin resistance and compensatory hyperinsulinism on these glands and, possibly, by direct effects of proinflammatory cytokines secreted into the circulation (Escobar-Morreale and San Millan, 2007) . We have proposed that women with PCOS may suffer from a vicious circle whereby androgen excess favors the abdominal deposition of body fat, and visceral fat facilitates further androgen excess by the mechanisms described above (Fig. 1 , Escobar-Morreale and San Millan, 2007) . However, it must be highlighted that, in order to develop PCOS in response to obesity and visceral fat accumulation, these women must have a primary defect in steroidogenesis that facilitates androgen secretion and excess, predisposing them toward androgen excess disorders (Escobar-Morreale and San Millan, 2007) . Such a primary defect has been demonstrated at the ovarian level because theca cells from patients with PCOS maintain the ability to secrete excessive amounts of androgens and their precursors even after several passes in cell culture (Wickenheisser et al., 2006) .
We have hypothesized that, as a group, women with PCOS represent a continuum in the severity of androgen excess. At one extreme of the continuum, androgen excess is severe enough to result in PCOS in some patients even in the absence of any triggering factor. At the other extreme of the continuum, very mild defects in androgen secretion only manifest clinically when amplified by the coexistence of obesity, abdominal adiposity and/or insulin resistance. Of note, reputed authors in the field consider obesity to be among 'secondary PCOS' phenotypes in which gonadal dysfunction improves or even resolves after weight loss (Pasquali et al., 2016) . The spectrum in the severity of the primary defect in androgen secretion may be one of the reasons explaining the heterogeneous association of PCOS with obesity and metabolic comorbidities (Fig. 2, Escobar-Morreale and San Millan, 2007) . The presence of a relatively mild defect in androgen secretion may also explain the association of PCOS with other exogenous and endogenous causes of hyperinsulinemia, such as type 1 diabetes (Escobar-Morreale and Roldán-Martín, 2016), congenital portosystemic shunt (Satoh et al., 2001) or insulinoma Figure 1 Abdominal adiposity and PCOS. The interplay between PCOS and abdominal adiposity may be the result of a vicious circle represented by the black arrows: androgen excess favors the abdominal deposition of body fat, and visceral fat facilitates androgen excess of ovarian and/or adrenal origin by the direct effects (white arrow) of several autocrine, paracrine and endocrine mediators, or indirectly by the induction of insulin resistance and hyperinsulinism. Reproduced with permission from Escobar-Morreale and San Millan (2007) . TNF, tumor necrosis factor; IL, interleukin; PCOS, polycystic ovary syndrome. (Murray et al., 2000; Stanciu et al., 2003) . In the latter, PCOS may resolve after surgical removal of the insulin-secreting tumor (Murray et al., 2000; Stanciu et al., 2003) , similarly to what happens with weight loss after bariatric surgery in severely obese women with the syndrome (Escobar-Morreale et al., 2005) . On the contrary, women without a primary defect in androgen secretion would not develop androgen excess and PCOS even in the presence of extreme obesity and/or insulin resistance, explaining the lack of gonadal dysfunction in many severely obese women (Escobar-Morreale et al., 2005) .
In obese men, rather than exerting direct effects on testicular function, adipose tissue excess and dysfunction appear to contribute to androgen deficiency by effects that likely involve the hypothalamic-pituitary level, resulting in inhibition of gonadotropin secretion (Saboor Aftab et al., 2013) . Among the mechanisms involved, inhibition of gonadotropin secretion by excessive peripheral estrogen production in adipose tissue should play a role because aromatase inhibitors may normalize testosterone concentrations in obese men (de Boer et al., 2005; de Ronde, 2007) . However, insulin resistance at the hypothalamic and pituitary levels (Bruning et al., 2000) and the inhibitory effect on gonadotropin secretion of inflammatory mediators secreted by adipose tissue, such as leptin, may also play a role in the pathophysiology of MOSH (Landry et al., 2013; Saboor Aftab et al., 2013) .
The pathophysiology of MOSH may involve a vicious circle whereby abdominal adiposity and obesity result in secondary hypogonadism, and androgen deficiency facilitates further deposition of body fat in the abdominal and visceral fat depots in parallel with a decrease in lean and muscle mass (Fig. 3 , Escobar-Morreale et al., 2014) . We have hypothesized that compared with women, early and chronic exposure to androgens predisposes men toward abdominal adiposity and adipose tissue dysfunction . But at the same time, the increase in lean and muscle mass resulting from chronic androgen exposure may have protective metabolic effects in them (EscobarMorreale et al., 2014) . When exercised regularly, the large muscle mass of adult men may provide protection against metabolic dysfunction by reducing the energy surplus (Felig and Wahren, 1975) and by maintaining the amount of visceral fat relative to total body mass at healthy levels. Any event that alters this delicate equilibrium such as a sedentary life-style, the normal ageing process or, as occurs in MOSH, the development of obesity and androgen deficiency, would lead to abdominal adiposity and metabolic disorders. But similarly to what happens with Figure 2 Pathophysiological heterogeneity in patients with PCOS. PCOS is the result of the interaction of a primary abnormality in androgen synthesis, manifesting as androgen excess, with environmental factors such as abdominal adiposity (red and white targets), obesity and insulin resistance. At one extreme (*), in some patients, the disorder is severe enough to result in PCOS even in the absence of triggering environmental factors. At the other extreme (**), a very mild defect in androgen secretion is amplified by the coexistence of abdominal adiposity, obesity and/or insulin resistance. Between the two extremes, there is a spectrum in the severity of the primary defect in androgen secretion, explaining the heterogeneity of patients with PCOS with regard to the presence of obesity and metabolic comorbidities. Yet, all patients share a primary defect in androgen secretion. Reproduced with permission from Escobar-Morreale and San Millan (2007) .
PCOS in severely obese women, MOSH is not universal in men presenting with severe obesity. The mechanisms predisposing men toward the development of MOSH remain largely unkown.
As occurs with other comorbidities of obesity (World Health Organization Fact Sheets, 2016) , the risk of obesity-associated gonadal dysfunction may increase with increases in BMI reaching, in our experience, very high prevalence rates in patients with severe obesity submitted to bariatric surgery (Escobar-Morreale et al., 2005; Calderon et al., 2016) .
In patients presenting with severe obesity, bariatric surgery is more effective than other therapeutic options, such as life-style intervention, dietary therapy, exercise, behavior modification and drugs, both in terms of weight loss outcomes and improvement and remission of weight-associated comorbidities (Colquitt et al., 2014) . With the present systematic review and meta-analysis, we aimed to confirm our previous findings from a relatively small series of women and men by obtaining a global estimate of the prevalence of obesity-associated gonadal dysfunction in patients submitted to bariatric procedures because of severe obesity, and evaluating the response to surgery in terms or resolution and/or improvement of these conditions and changes in circulating sex hormone concentrations.
Methods
We followed the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (Stroup et al., 2000) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (PRISMA; Moher et al., 2009).
Data sources and searches
We searched the PubMed and EMBASE online facilities introducing as MESH terms (bariatric surgery OR Roux-en-Y OR jejunocolic bypass OR jejunoileal bypass OR vertical banded gastroplasty OR biliopancreatic diversion OR duodenal switch OR obesity surgery OR gastric bypass OR sleeve gastrectomy OR gastric banding OR Scopinaro OR intestinal bypass) AND ((androgen deficiency OR hypogonadism OR decreased testosterone OR testosterone deficiency OR sperm OR spermatogenesis OR libido OR impotence OR sexual dysfunction OR erectile dysfunction OR gonadotropin OR infertility OR subfertility OR oligospermia OR azoospermia) OR (androgen excess OR hyperandrogenism OR PCOS OR polycystic ovarian syndrome OR polycystic ovarian disease OR polycystic ovaries OR hirsutism OR acne OR alopecia OR menstrual dysfunction OR anovulation OR infertility OR subfertility OR ovulation induction)).
Study selection
We included human studies published between 1996 and June 2016. The reference lists of the articles selected were also hand checked to identify studies missing in the primary search. There were no study format restrictions. We included articles showing data on prevalence of PCOS and/or MOSH among patients submitted to bariatric surgery using widely accepted criteria (Zawadzki and Dunaif, 1992 ; The Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group, 2004; Azziz et al., 2009; Tajar et al., 2010; Saboor Aftab et al., 2013) . Regarding PCOS in women, the 1990 National Institutes of Health (Zawadzki and Dunaif, 1992) circulating total and/or free testosterone concentrations, low or inappropriately normal gonadotropin concentrations and a BMI ≥30 kg/m 2 (Tajar et al., 2010; Saboor Aftab et al., 2013) . We also included studies in which women with PCOS or men with MOSH were re-evaluated after bariatric surgery and articles in which circulating sex hormone concentrations were analyzed before and after bariatric surgery. We selected articles containing at least one of these outcomes. Resolution of PCOS or MOSH after bariatric surgery was considered when signs and symptoms of these disorders dissapeared and/or improved to the extent that such a diagnosis could no longer be sustained using the same criteria applied for the initial diagnosis. We excluded articles in which the diagnosis of PCOS or MOSH were not directly established by the researchers or were not based on the criteria described above (Zawadzki and Dunaif, 1992 ; The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004; Azziz et al., 2009; Tajar et al., 2010; Saboor Aftab et al., 2013) . Hence, articles where the diagnosis of gonadal dysfunction relied on the use of questionnaires, self-report of symptoms, public database extraction or previous diagnosis, not confirmed by the authors of the original research were not included in the qualitative synthesis.
We also excluded articles written in languages other than English, French or Spanish. Finally, to avoid over-representation of cases, when several studies on the same series of patients have been published, only the report with the larger sample size was included in the meta-analysis.
Study selection was performed independently by three investigators (H.F.E.-M., E.S. and J.I.B.-C.). Disagreements were discussed and resolved by consensus or by arbitration by an author not involved in the search of the literature (M.L.-R).
Data extraction
The following data were extracted from the retrieved studies: author's names, year, publication date, country, sample size, diagnostic criteria for PCOS or MOSH, mean age, weight and BMI, prevalence of gonadal dysfunction before and/or after bariatric surgery, mean and standard deviation of circulating androgens, estrogens, sex hormone-binding globulin (SHBG) and gonadotropins before and at least 6 months after bariatric surgery. When the articles described these values at several time points during follow-up, the time point that included the largest number of patients was used, provided that at least 6 months had passed since surgery.
Quality assessment
The studies included in the prevalence meta-analyses were appraised for their methodological quality according to the Q-Index (Doi et al., 2015) . This index scores 6 quality scale variables which are then converted into quality ranks between 0 and 1 by dividing each score by the score of the highest scoring study in the group (Supplementary File 1) . For the metaanalysis of studies comparing circulating sex hormone concentrations before and after bariatric surgery, we used the Quality Assessment Tool for Before-After (Pre-Post) Studies with no Control Group (available at https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascularrisk-reduction/tools/before-after) that considers 11 'yes/no' items and gives one point for each affirmative answer. The total scores of each study were converted into quality ranks between 0 and 1 by dividing each score by the score of the highest scoring study in the group (Supplementary File 2) .
The Q-index and the Quality Assessment Tool for Before-After (PrePost) Studies with no Control Group final results were used to help reduce estimator variance by modeling redistribution of weights in the meta-analysis of prevalences and weighted mean differences (WMD) before and after bariatric surgery, respectively (Doi et al., 2015) .
Statistical analysis
Meta-analyses were performed using the MetaXL 5.3 program (http:// www.epigear.com/index_files/metaxl.html). Because of the heterogeneous nature of the studies in terms of age, race, ethnicity, criteria for the definition of PCOS and MOSH, bariatric surgical technique, and sex hormone assays, we used the quality effects model for meta-analyses (Doi et al., 2015) . The quality effects model, which relies on the use of the quality indexes described above to weight the studies, is more robust compared with fixed-or random-effects models when analyzing heterogeneous studies.
Double arcsine transformations were applied to stabilize the variance in the meta-analyses of prevalence (Doi et al., 2015) . Forest plots showed the pooled prevalence estimates or WMD as diamonds, with their lateral points indicating CIs. The left hand column included study identifiers together with Cochran's Q and I 2 heterogeneity statistics whereas the right-hand columns included forest plots of the prevalences or WMD found in each of these studies (squares and horizontal lines representing CIs) and their corresponding numerical information. When 10 or more studies were analyzed (Sterne et al., 2005) , publication bias was assessed by funnel plots (Sterne and Egger, 2001 ) and Doi plots with Luis FuruyaKanamori indexes of asymmetry (Doi et al., 2015) . All P-values are twosided, and α = 0.05 was set as the level of statistical significance.
Results Figure 4 shows the PRISMA flow chart, from identification of studies to inclusion in the meta-analysis. After deleting duplicates, the abstracts of 757 articles were analyzed. We subsequently excluded 712 articles: 613 were entirely unrelated to the issue, 24 were abstracts, editorials, letters or case-reports, 12 were reviews, 38 were actually related to fertility issues and 25 were related to sexual dysfunction but not to gonadal dysfunction or sex hormone concentrations. The full-text of the remaining 45 articles was assessed for eligibility (Supplementary File 3). Of these, 16 articles were excluded: 4 did not contain usable data on prevalence of gonadal dysfunction or changes in sex hormone concentrations, 2 were excluded for using non-standard criteria for the diagnosis of gonadal dysfunction, 5 articles were excluded because the diagnosis of gonadal dysfunction was imprecise (self-reported, based on questionnaires or extracted from public databases), 4 were excluded because the data were already included in larger series by the same groups of authors, and 1 article was excluded as we did not obtain any answer for data clarification from the authors (Supplementary File 3) . Hence, 29 studies were included in the quantitative synthesis and in the different metaanalyses (Tables I-III and Supplementary File 3) .
Meta-analysis of prevalence of gonadal dysfunction
In severely obese patients submitted to bariatric surgery gonadal dysfunction was very prevalent. The pooled prevalence of PCOS in five studies including 352 severely obese women (Table I) was 36%, with a 95% CI (95CI) of 22% to 50% (Fig. 5, panel A) . Moreover, the pooled prevalence of MOSH in seven studies including 382 severely obese men (Table II) was even larger, since this disorder was found in 64% of these men, with a 95CI of 50% to 77% (Fig. 5, panel B) . Meta-analysis of resolution of gonadal dysfunction and associated symptoms after bariatric surgery
After bariatric surgery and the resulting weight loss gonadal dysfunction resolved in most patients presenting with PCOS or MOSH. The meta-analysis of the prevalence of resolution of PCOS included five studies (Table I ). The pooled prevalence of the resolution of PCOS in the 82 severely obese women included in the meta-analysis was 96% with a 95CI of 89-100% (Fig. 6, panel A) .
Signs and symptoms of PCOS also improved after bariatric surgery. Meta-analysis of four studies (Table I) including 56 patients showed resolution of hirsutism in 53% of hirsute women with a 95CI of 29-76% (Fig. 6, panel B) . Meta-analysis of six studies (Table I) including 128 women showed resolution of menstrual dysfunction in 96% of them, with a 95CI of 88-100% (Fig. 6, panel C) .
The meta-analysis of the prevalence of the resolution of MOSH included five studies (Table II) . The pooled prevalence of the resolution of MOSH in the 129 severely obese men included in the metaanalysis was 87% with a 95CI of 76-95% (Fig. 6, panel D) .
Meta-analysis of changes in sex hormone concentrations after bariatric surgery
For these meta-analyses, we included studies addressing changes in circulating sex hormone concentrations irrespective of whether or not the severely obese patients included had been diagnosed of gonadal dysfunction before surgery, because only a few articles investigated this diagnosis (Table III) .
SHBG concentrations (Fig. 7, panel B) increased after bariatric surgery in the 189 women (22.2 pmol/l, 95CI 1.6-46.8) and in the 328 men (22.4 pmol/l, 95CI 18.6-26.3) studied, and serum estradiol concentrations (Fig. 7 , panel C) decreased in the 46 women (−104 pmol/l, 95CI −171 to −39) and to a lesser extent in the 299 men (−22 pmol/l, 95CI −38 to −7) included in these meta-analyses. On the contrary, sexspecific changes were observed in serum androgen concentrations because total testosterone concentrations and indexes of free testosterone increased in men and decreased in women. Total testosterone increased in the 439 men included by 8.1 nmol/l with a 95CI of 5.6-10.6 and decreased in the 203 women by −0.7 nmol/l with a 95CI of −0.9 to −0.5 (Fig. 7, panel A) . Similarly, calculated free testosterone increased in 259 men by 77 pmol/l with a 95CI 48-105 (Fig. 8, panel B) but the free androgen index decreased in 122 women by −4.7, 95CI −7.4 to −1.9 (Fig. 8, panel A) , respectively. The decrease observed in women in serum androgens also included androstendione concentrations (n = 122, −2.4 nmol/l, 95CI −3.3 to −1.5, Fig. 8 , panel C) and DHEAS concentrations (n = 122, −1.2 μmol/l, 95CI −2.2 to 0.0, Fig. 8,  panel D) .
Serum gonadotropins, which were analyzed only in studies in men, increased after bariatric surgery. In 340 men, LH increased by 1 U/l with a 95CI of 0.7-1.4, whereas in 281 men, FSH increased by 1.8U/ l with a 95CI of 1.4-2.1 (Fig. 8, panels E and F, respectively) .
Finally, the possibility of publication bias was ascertained in metaanalyses that included 10 or more studies which were those reporting changes in sex hormone concentrations in men, by estimating asymmetry in funnel and Doi plots. Only minor asymmetry was found in these plots for SHBG concentrations, whereas no evidence for 
Table I
Characteristics of the studies about PCOS and associated traits included in meta-analyses and in the descriptive review.
Author ( publication bias was found in the case of total testosterone, estradiol and gonadotropins ( Supplementary Fig. S1 ).
Discussion
Prevalence of gonadal dysfunction in severely obese subjects submitted to bariatric surgery
Our present systematic review and meta-analysis of the literature indicates that gonadal dysfunction was very prevalent in severely obese patients submitted to bariatric surgery, with PCOS being present in one-third of women and MOSH being found in two-thirds of men. These figures are much higher that those reported in the general population and, in our opinion, may justify routine screening for gonadal dysfunction in these severely obese subjects. The prevalence of PCOS in the general population varies within the 5-15% range depending on the population being studied and on the criteria used for diagnosis (Asuncion et al., 2000; Sanchon et al., 2012; Yildiz et al., 2012) whereas male hypogonadism, as defined by decreased total testosterone levels, was present in~10-20% of men in the same age range of the obese men included in the studied reviewed here (Harman et al., 2001) .
Even though the data analyzed here may be biased since the patients included here were submitted to bariatric surgery and do not truly represent all severely obese subjects in the general population, the association of PCOS and MOSH with weight excess is not restricted to severe obesity: PCOS was found in 29% of overweight or obese women seeking advice for weight loss (Alvarez-Blasco et al., 2006) and MOSH was also present in 30-50% of men with Grades 1 and 2 obesity (Hofstra et al., 2008) . Therefore, the very large prevalences of gonadal dysfunction in women and men submitted to bariatric surgery confirms that their prevalences increase with increases in BMI, as occurs with other comorbidities of obesity (World Health Organization Fact Sheets, 2016).
Resolution of gonadal dysfunction after bariatric surgery
Importantly, the resolution of PCOS and MOSH after surgically induced weight loss in 96% and 87% of obese subjects presenting initially with these disorders makes bariatric surgery the most effective approach for both disorders in very obese patients. Complete resolution of PCOS in women and of secondary hypogonadism in men occurs rarely, if ever, with other therapeutic approaches that usually target symptom relief or replacement therapy, respectively (Ehrmann, 2005; Guay, 2009) , even though both PCOS and MOSH may improve after weight loss attained by diet and life-style modification (Norman et al., 2002; Hoeger, 2006; Rastrelli et al., 2015; Pasquali et al., 2016) . Unfortunately, therapeutic approaches based on diet and life-style changes are seldom effective on the long-term (Hainer et al., 2008) . Therefore, according to our present results, bariatric surgery should be offered to severely obese patients presenting with PCOS or MOSH as the most effective approach to treat gonadal dysfunction because resolution of both disorders has been described as soon as 6 months after surgery and may be maintained for mean follow-up periods as long as 28 and 47 months in some studies that have addressed the resolution of PCOS after bariatric procedures.
Surgically induced weight loss may not only provide a cosmetic effect on hirsutism in women but, given that resolution of menstrual and/or ovulatory dysfunction occur in almost all severely obese patients with PCOS after bariatric surgery, might also contribute to restoration of fertility in these women. In comparison, laparoscopic ovarian surgery restores ovulatory cycles in~50% of women with PCOS (ESHRE Capri Workshop Group, 2012), but it must be highlighted that this technique is usually reserved for the most severe anovulatory patients when clomiphene citrate, gonadotropins and/ or aromatase inhibitors have failed. Similarly, normalization of serum testosterone has the potential of improving fertility in severely obese men, although studies addressing spermatogenesis and not only androgen levels are urgently needed considering the discrepant results observed to date: small case-series have suggested deterioration of semen parameters (di Frega et al., 2005; Lazaros et al., 2012; Sermondade et al., 2012) whereas larger prospective studies have indicated neutral Legro et al., 2015) or even beneficial (El Bardisi et al., 2016) effects of surgically induced weight loss on seminal quality. Hence, the resolution of PCOS and MOSH in severely obese subjects submitted to bariatric surgery might suggest a potential beneficial effect of fertility, yet studies addressing Data are means ± SD. Abbreviations A, androstendione; DHEAS, dehydroepiandrosterone-sulfate; E1, estrone; E2, estradiol; FAI, free androgen index; NA, not available; SHBG, sex hormone-binding globulin. *Quality was scored according to the Quality Assessment Tool for Before-After (Pre-Post) Studies with no Control Group. infertility specifically and its possible resolution after massive weight loss are needed before reaching any valid conclusion. However, we must emphasize that studies focusing on the longterm duration of the resolution of obesity-associated gonadal dysfunction after bariatric surgery are lacking at present, especially in the case of MOSH, and weight regain, although usually small or moderate in magnitude, is certainly a possibility in these patients (Karmali et al., 2013) . Therefore, reappearance of obesity-associated gonadal dysfunction may occur after weight regain, as has been described for other metabolic comorbidities of obesity such as diabetes (Campos et al., 2013) , although this possibility has not been described or even explored to our best knowledge.
The remarkable rate of resolution of PCOS and MOSH after bariatric surgery provides strong evidence supporting a causal role of obesity and adipose tissue dysfunction in the development of gonadal dysfunction in severely obese subjects. However, it must be highlighted that gonadal dysfunction is not universal among severely obese subjects, and that both PCOS and secondary hypogonadism also occur in normal weight subjects. Therefore, gonadal dysfunction appears to develop with obesity only in individuals predisposed to PCOS or to MOSH, as will be discussed below.
Changes in sex hormones and SHBG and their implications for the pathophysiology of obesity-associated gonadal dysfunction
The changes observed in sex hormone concentrations following bariatric surgery provide some insights into the pathophysiological mechanisms and marked sexual dimorphism underlying obesityassociated gonadal dysfunction.
Resolution of gonadal dysfunction in women and men was paralleled by similar increases in SHBG concentrations in both sexes, indicating that obesity was somehow involved in the decreased concentrations of this globulin. Synthesis and secretion of SHBG in the liver depends on the balance between stimuli such as estrogens and thyroid hormones, and inhibitory influences such as androgens and insulin, liver fat and inflammatory mediators (Toscano et al., 1992; Pugeat et al., 1996; Thaler et al., 2015) . Considering the disparate androgen levels associated with obesity in women and men, and the increase observed in SHBG concentrations despite decreasing estradiol levels following weight loss in both sexes, it appears that inhibitory influences arising from adipose tissue dominate the picture in severe obesity. In this regard, recent data suggest that liver fat excess, Please note that the dual-scale x-axis used for total testosterone concentrations in panel A, which explains the non-symmetrical CI in some studies. A quality effects model was used for meta-analyses. The characteristics of the populations included in the studies are summarized in Table III . Funnel and Doi plots of total testosterone, SHBG and estradiol in men can be found in Supplementary Fig. S1 . These plots were not drawn for women because there were <10 studies included in these meta-analyses. WMD, weighted mean differences; SHBG, sex hormone-binding globulin. Table III . Funnel and Doi plots of free testosterone and gonadotropins in men can be found in Supplementary Fig. S1 . These plots were not drawn for women because there were <10 studies included in these meta-analyses.
and not only hyperinsulinemia, is among the major inhibitory influences on SHBG secretion in obese subjects, in a process that likely involves the secretion of proinflammatory cytokines by this ectopic adipose tissue (Simo et al., 2015) .
The decrease observed in men and women in their serum estradiol concentrations may simply reflect the decrease, with weight loss, in the production of estrogens in adipose tissue from testosterone and steroid precursors (Nelson and Bulun, 2001) . Of note, aromatase inhibition with drugs such as letrozole may be useful in ovulation induction in obese women with PCOS (Franik et al., 2014; Balen et al., 2016) and may reverse MOSH in obese men (de Boer et al., 2005; de Ronde, 2007) , indicating the importance of increased aromatase activity in the pathophysiology of obesity-associated gonadal dysfunction. But the changes observed in serum androgens and gonadotropins merit further explanation and might be intimately related to the strikingly different pathophysiology of obesity-associated gonadal dysfunction in women and men.
In severely obese women with PCOS, serum androgen concentrations normalized following bariatric surgery (Escobar-Morreale et al., 2005; Eid et al., 2014; Turkmen et al., 2015) after a decrease that is similar in magnitude to the decline observed in these hormones in PCOS patients submitted to laparoscopic ovarian surgery (Hendriks et al., 2007) . However, after bariatric procedures, the increase in SHBG concentrations (thereby reducing the amount of testosterone available to target tissues) and the improvement in insulin resistance (ameliorating endogenous hyperinsulinism and ovarian androgen hypersecretion), which seldom occur after laparoscopic ovarian surgery (Hendriks et al., 2007) , may also contribute to the striking resolution rate of PCOS observed after surgically induced weight loss.
In contrast, according to our present meta-analyses, the resolution of MOSH in men submitted to bariatric surgery occurred in parallel to the increase in luteinizing hormone, follicle-stimulating hormone and total and free testosterone concentrations (Aarts et al., 2014) , even overcoming the increase in SHBG concentrations mentioned above. These changes further support the major role that inhibition of the hypothalamic-gonadotropin axis by factors derived from adipose tissue plays in the development of MOSH (Saboor Aftab et al., 2013) .
The changes in serum androgen concentrations were not restricted to women with PCOS or men with MOSH, but were also present in series of severely obese patients submitted to bariatric surgery in whom the diagnosis of these disorders was not specified (Table III) . This finding suggests that androgen secretion also improves in the considerably large subset of severely obese patients not presenting with obesity-associated gonadal dysfunction. Whether or not the improvement of serum androgen concentrations Figure 9 Relevance of obesity-associated gonadal dysfunctions for the clinical management of severe obesity in men and women. *Women desiring fertility must be advised to postpone pregnancy for at least 1 year after bariatric surgery and to maintain close nutritional and obstetric support throughout pregnancy.
† The impact of surgically induced weight loss on male fertility and sterility is unclear at present and men presenting with fertility desire and an abnormal semen analysis may need hormonal treatment and even assisted reproductive techniques.
represent an actual benefit for the health of these men and women remains to be investigated. Additionally, our meta-analyses indicate that obesity-associated gonadal dysfunction is not universal in patients presenting with severe obesity submitted to bariatric surgery. As described earlier, the~60% of women who show no evidence of androgen excess in our metaanalysis despite being severely obese may simply lack any primary defect in androgen synthesis and secretion, precluding the development of PCOS even in the presence of severe abdominal adiposity and insulin resistance (Escobar-Morreale and San Millan, 2007) . However, very little is known about the factors underlying the development of MOSH in severely obese men and, conversely, why~30% of severely obese men do not develop this disorder. Compared with severely obese men maintaining normal serum testosterone concentrations, those presenting with MOSH tended to have a higher BMI (Pellitero et al., 2012; Aarts et al., 2014) and present with cardiometabolic dysfunction such as diabetes and hypertension more frequently compared with their normoandrogenemic counterparts (Aarts et al., 2014) . The association of MOSH with hyperglycemia was also present in a series in which men with or without MOSH had similar BMI, even though patients with MOSH were older (Calderon et al., 2016) and advancing age is one of the major causes of primary and secondary hypogonadism in the general population (Golan et al., 2015) .
Aside from more severe grades of obesity, diabetes and older age, the factors predisposing severely obese men toward the development of MOSH remain largely unknown. For example, the possibility that genetic variation in genes encoding proteins involved in androgen and estrogen synthesis, secretion, transport, metabolism, regulation or action, such as AR, ESR1, ESR2, CYP19A1, CYP17A1, SHBG, SRD5A2, LHB and LHCGR may influence the development of MOSH has not been explored to date. These genes should be considered candidates for MOSH as they encode proteins that are key players in the pathophysiologic pathways described above. Moreover, possible differences among obese subjects with or without MOSH in body composition parameters such as adipose tissue distribution in the subcutaneous and visceral depots and amount of muscle and lean body mass remain to be explored, and the same occurs for acquired and environmental factors such as diet, exercise, life-style, drugs and endocrine disruptors. Therefore, carefully designed studies in which severely obese men presenting with MOSH are matched with similarly obese normoandrogenemic men in terms of BMI, age and prevalence of metabolic dysfunction are urgently needed in order to identify the pathophysiologic mechanisms, whether genetic or acquired, that underlie predisposition to MOSH.
Limitations of the study
Even though the results of the present systematic review and metaanalysis may appear convincing, we must point out several limitations that preclude reaching definite conclusions on the issue. First, the number of studies is relatively small, especially with regard to PCOS in women. Second, the sample size of some studies was small, a limitation that affects especially the studies in women and the studies addressing the changes in gonadal dysfunction following bariatric surgery. Third, we were not able to estimate the prevalence of female androgen excess disorders other than PCOS, and their resolution rate after bariatric surgery: only one study (Escobar-Morreale et al., 2005) included prevalence data about idiopathic hyperandrogenism (present in 5 of 36 severely obese women submitted to bariatric surgery) and no study addressed adrenal and peripheral androgen excess phenotypes. Fourth, the definition of MOSH in almost all studies relied solely on the finding of decreased serum testosterone concentrations and did not consider other symptoms and signs of hypogonadism. This possibly lead to overestimation of the prevalence of MOSH among severely obese men, because serum testosterone concentrations decrease with increasing BMI and the reference values in these studies were not based on otherwise healthy weight-matched populations. Fifth, the duration of follow-up after bariatric surgery in many studies was relatively short, and the possibility of a relapse of obesity-associated gonadal dysfunction in subjects who regain weight in the long-term has not been explored to date. On the contrary, the heterogeneity in the studies included here was taken into account by the Quality Effects Model used for meta-analysis and publication bias was unlikely in most of the variables meta-analyzed.
Relevance for clinical practice
With all due prudence, considering the limitations of our study and the large gaps existing in current knowledge about the long-term effects of surgically induced weight loss on gonadal function, we might extrapolate our current findings to the management of severe obesity (Fig. 9) . On the one hand, the very large prevalences of both PCOS and MOSH in women and men submitted to bariatric surgery justify, in our opinion, their universal screening in subjects with severe obesity. On the other hand, in the subset of severely obese subjects diagnosed with PCOS or MOSH, bariatric surgery has shown potential for a substantial amelioration and even the resolution of signs, symptoms and disorders of gonadal dysfunction in parallel to the improvement of other comorbidities of obesity. Current guidelines indicate bariatric surgery for obese patients with a BMI ≥40 kg/m 2 or a BMI 35-40 kg/m 2 with comorbidities in which surgically induced weight loss is expected to improve the disorder (Fried et al., 2013) . Hence, we suggest considering PCOS and MOSH among the disorders that may help when deciding about bariatric surgery in patients presenting with a BMI 35-40 kg/m 2 as an effective approach to improve clinical signs and symptoms of androgen excess in women or deficiency in men, including sexual dysfunction (Wingfield et al., 2016) . Regarding infertility, surgically induced weight loss may improve fertility rates in women (Milone et al., 2016) and, provided that pregnancy is delayed until the initial rapid weight loss phase is finished and proper nutritional and obstetric support is given during follow-up, the risks for pregnancy of bariatric surgery, intrauterine growth restriction, prematurity, complications of surgery such as internal hernia, are compensated by the prevention of comorbid conditions of severe obesity such as gestational diabetes, preeclampsia and fetal macrosomy (Guelinckx et al., 2009) . On the contrary, the effects of bariatric surgery in men presenting with MOSH and abnormal semen analysis are unclear at present (Reis and Dias, 2012) , and even after bariatric surgery, infertile men may need additional hormonal treatment in order to restore fertility.
Conclusions
In summary, gonadal dysfunction is among the most prevalent comorbidities in patients with severe obesity and should be ruled out routinely during their initial diagnostic workup. Considering the excellent response of both PCOS and MOSH to marked weight loss, bariatric surgery could be offered as a first-line therapeutic approach to severely obese patients presenting with obesityassociated gonadal dysfunction.
